|
We asked 40 pharma leaders, what do you think is the biggest hurdle when it comes to effective quality management?
| Bureacracy |
25% |
| Too Many Priorities |
12% |
| Lack of Communication |
24% |
| Outdated Traditions |
31% |
| Complacency |
8% |
 |
|
|
|
|
|
|
|
|
8 May, 2012 |
|
| In this Issue |
UK Advances Anticounterfeiting Strategy
In the last five years, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has seized counterfeit drugs worth more than £25 million ($41 million), but the war isn’t over yet. Counterfeit products are still a threat to the UK, which is why the Agency has launched a new anticounterfeiting strategy called the Falsified Medical Products Strategy 2012–2015.
Read more... |
Looking for Success in Emerging Markets? Then What's Your Corporate Value Proposition?
Pharma companies entering the emerging markets are under pressure to offer a convincing Corporate Value Proposition (CVP). But what is a good CVP, asks Nigel Thompson, and when should you use it? More... |
 |
FDA Issues Warning Letters to 10 Companies for Lack of Safety Evidence
Last week FDA issued Warning Letters to 10 companies that manufacture and distribute dietary supplements that contain dimethylamylamine (DMAA). FDA cited the companies for marketing the supplements without submitting evidence that the products are safe. More... |
Heady Ideas for Digital Healthcare Marketing
If you really want to know what’s on a patient’s mind, it’s best to skip the small talk and go straight to the brain waves, as demonstrated by Neuro Insight CEO Pranav Yadav in the lead-off presentation at Chandler Chicco’s Pioneers in Digital Health conference last week. More...
|
| Product Profile |
| NNIT |
 GxP Cloud now with SaaS
With validated GxP applications ready as SaaS in NNIT's GxP Cloud you can save deployment and validation costs as well as time.
 Read more |
| Sciformix |
 Establishing Case Quality Metrics - defining and using quality metrics for adverse events case processing.  Read more
|
| Case Study |
Reducing outsourcing costs and cycle-times
 Discover how a biotech saved $600,000 on a Phase II contract, compressed the contracting cycle-time from three months to two weeks, and formed a more constructive and collaborative working relationship with their CRO.
 Download the case study today.
|
| Event Profile |
Global Publication Planning & Clinical Trial Registries Forum
Strategies for Effective and Compliant Data Dissemination and Coordination
11-12 June 2012
Amsterdam, Netherlands
The relationship between journal publications and trial databases is essential for full disclosure of clinical results information to the public. At the Global Publication Planning and Clinical Trial Registries Forum.
 Read more |
|
|
|
|
|
|
